Regeneron Pharmaceuticals, Inc. REGN | NASDAQ
Next Earnings: Mar 04, 2026
Company Overview:
10 Year REGN Performance Metrics:
REGN Dividend Payments, Yield & Share Price charts
Unlock All Reports & Research Dividend Stocks like a BOSS!
Get 3 months FREE!
REGN Dividend Safety: Payout & Dividend to Free Cash Flow Ratios.
REGN Earnings, Revenue, Cash & Debt, Shares Outstaning:
Revenue, EPS, Net Income & Ebitda - Estimates VS Actual:
Ratios, Profit Margins & Return on Capital:
REGN Dividends Info:
REGN Dividend History: Dates, Payments & Yield list
Below is a schedule of all REGN dividend payments, ex-dates, share price on the day of the payment as well as TTM & forward yield
| Ex-Date | Payment Date | Amount | TTM Yield | Forward Yield | Price on Ex-Date |
|---|---|---|---|---|---|
| 02/20/2026 | 03/05/2026 | $0.940 | 0.46% | 0% | $0.00 |
| 11/20/2025 | 12/05/2025 | $0.880 | 0.48% | 0.49% | $718.36 |
| 08/18/2025 | 09/03/2025 | $0.880 | 0.46% | 0.62% | $563.80 |
| 05/20/2025 | 06/06/2025 | $0.880 | 0.29% | 0.71% | $493.22 |
| 02/20/2025 | 03/20/2025 | $0.880 | 0.13% | 0.53% | $662.62 |
Projected Future Returns & Dividends for REGN
Based on past 10-year performance, here are REGN growth metrics:
Share price CAGR of +6.67%
Dividend CAGR of +7.12%
Using REGN CAGR metrics, we can estimate that your initial $10000 investment, over the next 10 years, should grow as follows:
| REGN (DRIP) | REGN - No DRIP | |
|---|---|---|
| Current Price | $766.66 | $766.66 |
| Start Shares | 13.04 | 13.04 |
| Start Value | $10,000 | $10,000 |
| After 10 years: | ||
| Final Share Count | 13.71 | 13.04 |
| Dividends Payment | $1.87 | $1.87 |
| Annual Dividends | $103 | $98 |
| Yield on cost | 1.03% | 0.98% |
| Share Price | $1,370.88 | $1,370.88 |
| Total Dividends | $700 | $682 |
| Final Value | $18,797 | $18,563 |
NOTE: Above numbers are our estimate based on REGN's Dividend and Price CAGR over past 10 years.
These numbers should only be considered as "potential future returns"! DRIP assumes reinvesting dividends; No-DRIP assumes collecting dividends as cash.
We cannot guarantee that your actual returns will meet these estimates.
Get the best Dividend Stock Research Tools:
Get 3 months FREE!
Company Info
Regeneron Pharmaceuticals, Inc. (REGN) had its IPO on 1991-04-02, and is trader on NASDAQ stock exchange.
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma;Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
REGN website: https://www.regeneron.com
Get Full Access to All Reports with DRIPCalc PRO
Get 3 months FREE!
